SCHEMBL3045901

SCHEMBL3045901

COc1cc2c(cc1OCc1ccccc1)CCN(Cc1cccc(OC(C)C)c1)C2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.68
CHRNA7 P36544 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.57
ABCB1 P08183 11/20 0.54
ABCC1 P33527 4/20 0.53
ABCG2 Q9UNQ0 2/20 0.51
KDM4E B2RXH2 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
KMT2A Q03164 1/20 0.50
CHRM2 P08172 1/20 0.50
HTR1A P08908 1/20 0.50
CHRM3 P20309 1/20 0.50
DRD4 P21917 1/20 0.50
ADRA1D P25100 1/20 0.50
HTR2C P28335 1/20 0.50
ADRA1A P35348 1/20 0.50
ADRA1B P35368 1/20 0.50
DRD3 P35462 1/20 0.50
HTR2B P41595 1/20 0.50
SLC6A3 Q01959 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3059849 0.91 REV1 (0.74) REV1CHRNA7L3MBTL1ABCB1ABCC1
SCHEMBL3055739 0.89 REV1 (0.72) REV1CHRNA7L3MBTL1ABCB1ABCC1
SCHEMBL3049298 0.89 REV1 (0.66) REV1CHRNA7L3MBTL1ABCB1ABCC1
SCHEMBL3055433 0.88 REV1 (0.70) REV1CHRNA7L3MBTL1ABCB1ABCC1
SCHEMBL3042428 0.88 REV1 (0.64) REV1CHRNA7L3MBTL1ABCB1ABCC1
SCHEMBL3050371 0.86 REV1 (0.84) REV1CHRNA7ABCB1ABCC1ABCG2
SCHEMBL3052241 0.86 REV1 (0.76) REV1CHRNA7L3MBTL1ABCB1ABCC1
SCHEMBL3668878 0.85 REV1 (0.66) REV1CHRNA7L3MBTL1ABCB1ABCC1
SCHEMBL3051578 0.85 DHCR7 (0.66) REV1ABCB1ABCC1ABCG2KDM4E
SCHEMBL3046416 0.85 REV1 (0.71) REV1CHRNA7ABCB1ABCC1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US claimed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC REV1 1520/4885CHRNA7 4760/4885L3MBTL1 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.